alexa Molecular-guided Therapeutic Trials In Pediatric Cancer
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Giselle Sholler and Jessica Foley
ScientificTracks Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.002
Abstract
A fundamental challenge in the area of targeted cancer treatment is how to identify optimal therapeutic combinations that can treat heterogeneous tumors that are both highly adaptive and that exhibit significant inter- and intra-patient variation. Our research program outlines an approach by which we can utilize our expanding knowledge of molecular networks and the mechanisms of action of a growing pharmacopeia to deliver targeted combinations of effective therapies to pediatric cancer patients. The primary objective of our studies have been to evaluate the feasibility and safety of using predictive modeling based on genome-wide mRNA expression profiles and DNA mutations of tumor biopsies to make real-time treatment decisions. Our initial study has shown that the total time from date of biopsy to tumor board was 6-11 days (95% CI: 7.5-10.2) and 7-20 days to treatment (95% CI: 8.9-16.1). The tumor board, which consisted of pediatric oncologists from 15 sites across the US, pharmacists, bioinformatians, pathologists, created individualized therapy regimens for all subjects. Tumors were grown in culture and in mice xenograftsfor validation studies of predicted drug sensitivity. This study has shown that it is feasible to obtain real-time genomic profiling for molecularly guided therapy for use in treatment decision making. All regimens were safe without any unexpected serious adverse events proving that the molecular tumor board is able to make safe decisions similar to hospital tumor boards making treatment decisions without molecular information on the patients. The program is expanding to include DNA exome and RNA sequencing analysis.
Biography
Giselle Sholler, MD, MSc is currently the Chair of the Neuroblasotma and Medulloblastoma Translational Research Consortium. She is the Haworth Family Endowed Director of Innovative Therapeutics Clinic and Head of the Pediatric Oncology Translational Research Programin Pediatric Oncology at Helen DeVos Children?s Hospital, Grand Rapids, MI as well as Associate Professor in the College of Human Medicine at Michigan State University, Grand Rapids, MI. She received her MD from New York Medical College, in Valhalla, NY. She was a resident in pediatrics and, subsequently, a fellow in pediatric hematology/oncology at Brown University, before coming to international prominence for her work with relapsed neuroblastoma at the University of Vermont. She then transferred her program to Helen DeVos Children?s Hospital, Grand Rapids, MI. As Haworth Endowed Director of the Innovative Therapeutics Clinic, she focuses on early phase clinical trials for pediatric cancers. Her lab research at HDVCH is focused on neuroblastoma and identifying new therapies through preclinical development leading to Phase I clinical trials as well as genomic analysis of tumors for children. With the NMTRC, she opened the first FDA-approved personalized medicine clinical trial in pediatric oncology and has expanded this across 15 centers across the US.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords